pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

FTC sues Hims & Hers over alleged health data sharing and deceptive billing practices

Jul 29, 2026·read at Endpoints ↗RegulatoryNegative

The Federal Trade Commission filed a lawsuit against Hims & Hers, a telehealth company based in San Francisco, accusing it of improper handling of patient information.

According to the complaint, the company allegedly disclosed users' sensitive health data to third-party advertisers without proper consent, raising privacy concerns.

The FTC also claims the firm engaged in deceptive billing practices, misleading consumers about charges. The lawsuit highlights regulatory scrutiny of digital health platforms.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “FTC sues Hims for sharing sensitive health information, billing practices”

read at Endpoints ↗
83 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoUS releases $600M in funding for global health group GaviEndpoints
  • 4h agoUpdated: FDA adcomm votes down Capricor's DMD therapy over efficacyEndpoints
  • 5h agoTeva is confident it has time to brace for tariffs on non-US genericsEndpoints
  • 5h agoNYU's Neil Vasan departs as acting chair of FDA's cancer drug advisory panelEndpoints
  • 7h agoAtea's hep C pill equal to Gilead's; AbCellera inks second deal in two monthsEndpoints